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The tumorigenic process leading to colorectal carcinoma forma-
tion involves multiple genetic alterations (Fearon and Vogelstein,
1990). Genes whose regulation or expression is known to be
perturbed in colorectal carcinomas include tumour suppressor
genes such as p53 and APC (Baker et al, 1989; Groden et al,
1991), proto-oncogenes such as myc and ras (Erisman et al, 1985;
Bos et al, 1987), and genes of the mismatch repair system such as
hMSH2 and hMLH1 (Fishel et al, 1993; Bronner et al, 1994). To
date, however, no common series of genetic changes has been
detected in all colorectal carcinomas, suggesting that tumori-
genesis may result via a variety of pathways.
Most recently a novel putative tumour suppressor gene called
FHIT (Fragile Histidine Triad) has been isolated and characterized
(Ohta et al, 1996; Sozzi et al, 1996a). This gene resides at chromo-
somal location 3p14.2, an area known to undergo allelic loss in a
variety of cancers, a phenomenon usually considered to be sugges-
tive of the location of a tumour suppressor gene (Murphree and
Benedict, 1984; Knudson, 1985). This gene spans the aphidicolin-
inducible fragile site, FRA3B, a site first implicated in tumorigen-
esis in a family with renal cell carcinoma (Cohen et al, 1979; Wang
and Perkins, 1984). Abnormalities of the FHIT locus were found
in many established cell lines, and the gene was found to be
abnormally transcribed in primary tumours of the digestive tract
including oesophagus, stomach and colon (Ohta et al, 1996), the
lung (Sozzi et al, 1996a) and breast (Negrini et al, 1996), with
primary lesions affecting either overall RNA levels or specifically
exons 5 and 8. These results suggest that FHIT could be abnormal
in several common human tumour types. This is not, however,
supported by one other group who have examined FHIT in a
number of colorectal cancer cell lines and xenografts
(Thiagalingam et al, 1996), and find a relatively low rate of
abnormal FHIT expression.
The FHIT protein is a member of the histidine triad (HIT)
family. FHIT’s closest relatives are the yeast Schizosaccharomyces
pombe diadenosine tetraphosphate hydrolase (aph 1) and a
Saccharomyces cerevisiae putative aph gene (Huang et al, 1995).
The HIT family represents an evolutionarily conserved group of
small (14–22 kDa) proteins defined by two similarity blocks, one
of which contains the H´H´H (HIT) motif. Interestingly, these
homology blocks correspond to exons 5 and 8 of FHIT – both
implicated in tumorigenesis. The first HIT protein to be described
– protein kinase C (PKC) inhibitor-1 (PKCI-1) or HINT (histidine
triad nucleotide-binding protein) – was isolated by Walsh from
bovine brain (Pearson et al, 1990). Subsequently, human PKCI-
1/HINT was identified in two separate yeast two hybrid screens,
through interactions with either the regulatory region of PKCb
(Lima et al, 1996), or the ATDC gene product (Brzoska et al,
1995), which was isolated by complementation of the ionizing
radiation sensitivity of ataxia telangiectasia (group D) cell lines
(Kapp et al, 1992).
The role of FHIT aberrations in colorectal adenocarcinomas is
in itself unclear. While altered FHIT transcripts have been identi-
fied in a range of tumour cell lines including those derived from
the colonic adenocarcinomas (Ohta et al, 1996), other groups do
not find a high frequency of altered transcripts (Thiagalingam et
al, 1996), and so have suggested that FHIT may play little or no
role in colorectal tumorigenesis.
Perhaps more confusingly while some groups detect aberrant
transcripts only in the adenocarcinoma (Ohta et al, 1996) other
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groups have detected aberrant transcripts in normal colonic
mucosae (Chen et al, 1997) similar to the situation found with
other tumour types (Heubner et al, 1998). However, reports that
show that transfection of wild-type FHIT into gastrointestinal
tumour-derived cell lines (Siprashvili et al, 1997) is able to revert
the tumorigeneic phenotype suggest that FHIT may well play a
role in gastrointestinal and colorectal tumorigenesis. As such we
undertook to define the status of FHIT and PKCI-1/HINT tran-
scripts in a panel of primary colorectal adenocarcinomas.
MATERIALS AND METHODS
Patients and tumours
Samples consisted of 45 fresh, flash-frozen colorectal adenocarci-
nomas, each consisting of at least 70% neoplastic cells as verified
histologically. All samples consisted of single adenocarcinomas,
and patients with multiple carcinomas were excluded from the
cohort. Tumours were staged Dukes’ stage A–D by Turnbull’s
modification (Turnbull et al, 1967) of Dukes’ original staging
(Dukes, 1932).
RNA extraction and first strand cDNA synthesis
Total RNA was extracted from tumour samples using Trizol®
Reagent (Life Technologies, Gaithersburg, MD, USA). RNA was
resuspended and solubilized in RNAase free water. Reverse tran-
scription was performed in 20 ml final volume containing 2 mg
total RNA, 30 ng random primers, 10 mM dithiotreitol (DTT),
0.5 mM dNTPs, 50 mM Tris–HCl (pH 8.3), 75 mM potassium
chloride, 3 mM magnesium chloride and 200 units Superscript II
(Life Technologies). The reaction was incubated for 10 min at
25°C, followed by 50 min at 42°C and terminated by heating at
90°C for 5 min. Integrity of all samples was verified by amplifying
a 511 base pair fragment of the b-actin message using primers
B1: 5¢-GAAATCGTGCGTGACATTAA-3¢ and B2: 5¢-CTAGA-
AGCATTTGCGGTGGA-3¢.
FHIT amplification and DNA sequencing
The primers used for the RT-PCR analysis of FHIT were as
described by Ohta et al (1996). A total of 5 ml of first-strand cDNA
reaction from above was incubated with 0.8 mM of primers 5U2
and 3D2 in a total volume of 50 ml also containing 50 mM of each
dNTP, 5% dimethylsulphoxide, 0.5 mM spermidine and 2.5 U Taq
DNA polymerase (Qiagen, Hilden, Germany) in 1 ´ polymerase
chain reaction (PCR) buffer (Qiagen). PCR reactions involved an
initial denaturation at 95°C for 5 min followed by 35 cycles of
1 min denature at 95°C, 1 min annealing at 62°C and 1 min exten-
sion at 72°C, followed by a final extension at 72°C for 10 min. A
second nested PCR reaction was performed with 2 ml of first-
round PCR reaction in total volume of 50 ml. The reagent condi-
tions were as for first round amplification except that primers 5U1
and 3D1 replaced those used in the first-round amplification. PCR
products were analysed on either a 1% agarose gel or a 1.8%
Metaphor gel (FMC Rockland, ME, USA). The products were
excised from the gel matrix and purified using the Qiaex PCR
Purification Kit (Qiagen). DNA sequencing reactions were
performed using the Big Dye Termination reaction kit (PE Applied
Biosystems, Foster City, CA, USA) on approximately 60–90 ng of
template from above. Analysis was undertaken on an automated
ABI 377-18 DNA Sequencer (PE Applied Biosystems).
PKCI-1/HINT amplification and DNA sequencing
A 550 base pair fragment of cDNA containing the entire coding
sequence of the PKCI-1/HINT message was amplified from
first-strand cDNA (as above) using 0.25 mM of primers : PKU : 5¢-
GAGAGAGGCCGAGATGGCAG-3¢ and PKD : 5¢-TAGCCATG-
CAACAATGTCTT-3¢ in a total reaction volume of 100 ml
containing 20 ml of first-strand cDNA (from above), 0.2 mM of
each dNTP, 1.5 mM magnesium chloride and 2.5 U Taq DNA
polymerase (Promega, Madison, WI, USA) in 1 ´ PCR Buffer A
(Promega). Reaction conditions included an initial denaturation of
5 min at 95°C followed by 30 cycles of 1 min denaturation at
95°C, 1 min annealing at 52°C and 1 min extension at 72°C,
followed by a final extension of 10 min at 72°C. PCR products
were analysed on 1% agarose gels, and the products excised from
the gel matrix and purified using the Qiaex II purification kit
(Qiagen). DNA sequencing was undertaken as above.
RESULTS
We examined the message integrity of the HIT family genes FHIT
and PKCI-1/HINT from 45 colorectal adenocarcinomas and their
matched normal mucosa by a combination of reverse transcription
PCR (RT-PCR) and DNA sequencing. Samples consisted of two
Duke’s stage A (tumour confined to muscularis propria); 13
Dukes’ stage B (tumour penetrated through muscularis propria);
14 Dukes’ stage C (involvement of regional lymph nodes) and 16
Dukes’ stage D (evident distant metastasis) with staging according
to Turnbull’s modification (Turnbull et al, 1967) of Dukes’ orig-
inal staging (Dukes, 1932). All tumour samples contained at least
70% neoplastic cells as assessed histologically. Total RNA
integrity was confirmed by amplification via RT-PCR of a 511
base pair fragment of the b-actin message (Figure 1).
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Figure 1 RT-PCR analysis of transcripts expressed in eight colorectal
tumours (T) and corresponding matching normal mucosa (M) from the same
patients. Transcripts are shown for Fragile Histidine Triad (FHIT: top panel);
protein kinase C inhibitor-1 (PKCI-1: middle panel) and b-actin (bottom
panel). The position of the bands from Phi x174 DNA digested with HaeIII are
also shown. Truncated FHIT transcripts can be seen in tumour samples 1, 3
and 6876 J Elnatan et al
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Table 1 Classes of FHIT transcripts in colorectal adenocarcinomas by stage
Tumour stage Wild-type Insertions Deletions Mutations
A nflt+Dex10/11b Dex4–6+Dex10/11b
B nflt Dex4 Dex4–6+Ins46b+Dex8+Dex10/11b
nflt+Dex10/11b Dex4+Dex10/11b Dex4–6+Ins14b
Dex4–6+Dex10/11b Dex4–7+Ins138b
Dex4–8 Dex4–7+Ins138b+Dex10/11b
Dex4–8+Dex10/11b Dex5–7+Ins93b+Dex10/11b
Dex5–7+Dex10/11b Dex6–8+Ins101b+Dex10/11b
Dex5–8
Dex5–8+Dex10/11b
Dex8
C nflt Dex4
nflt+Dex10/11b Dex4+Dex10/11b
Dex4–6
Dex4–6+Dex10/11b
Dex4*–6+Dex10/11b
Dex4–8+Dex10/11b
Dex4*–10*
Dex5–7
Dex5–7+Dex10/11b
Dex5–8+Dex10/11b
D nftl Dex4–6 nflt+pm37Q–L
nflt+Dex10/11b Dex4–7
Dex4–7+Dex10/11b
Dex4–8+Dex10/11b
Dex5–6
Dex5–6+Dex10/11b
Dex5–7
Dex5–8+Dex10/11b
Dex8
Dex8+Dex10/11b
A total of 102 FHIT transcripts detected in 45 colorectal adenocarcinomas were fully characterized. Nftl: normal full-length transcript; D: deletion; ex: exon; pm:
point mutation; Ins: insertion. Unless indicated by* deletions are in frame.
Figure 2 Electrophoretic and sequence analysis of FHIT transcripts. Three products resolved by agarose gel electrophoresis after RT-PCR using FHIT
specific primers were isolated and analysed by DNA sequencing using an automated DNA Sequencer. Products are normal full-length FHIT (nflt); transcript
showing in-frame deletion of exons 5–7 (Dex5–7) and transcript showing in-frame deletion of exons 4–6 (Dex4–6). In the two truncated products the position of
the His98 polymorphism is indicated. Expression of the polymorphic site in this sample is homozygousHIT genes in colorectal cancer 877
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Amplification of the message from PKCI-1/HINT was under-
taken with primers which enabled amplification of the whole
coding region. In each case only a single product corresponding to
the expected size of the full-length product was detected in both
the adenocarcinoma samples and the matched normal mucosa
from the same patient (Figure 1). To detect any possible sequence
alterations, each PCR product was fully sequenced on an auto-
mated ABI 377-18 DNA Sequencer. No sequence variations were
seen in any product.
Amplification of messages of the FHIT gene was undertaken by
a two-stage nested PCR strategy. Initial attempts to undertake a
single-round amplification proved unsuccessful, probably due to
low message levels (data not shown). The two-stage nested PCR
methodology of Ohta et al (1996) was sufficient to identify
multiple transcripts in tumour samples. Patterns of amplification
were complex, with some tumours giving rise to as many as six
separate products. In no case was a PCR product of less than full-
length detected in any of the matched mucosa samples (Figure 1).
Each product was initially identified through agarose gel electro-
phoresis and then the identity of the transcript determined by DNA
sequencing as above (Figures 1 and 2). Classes of transcript
detected are shown in Table 1 and Figure 3.
Three tumours gave no FHIT amplification product despite
repeated attempts. These RNA samples, however, were used to
successfully amplify both b-actin and PKCI-1/HINT messages,
suggesting that these tumours have lost or had silenced both copies
of the FHIT gene. These samples included two staged as Dukes’
stage D and one staged as Dukes’ stage B. Immunohistochemical
examination of these three samples confirmed the absence of
FHIT protein (data not shown).
A further six tumours gave only a single message corresponding
to the normal, full-length transcript (termed nflt). Tumour stages
were approximately equally represented, with the six tumours
consisting of two tumours each from Dukes’ stages B, C and D.
A total of 96 transcripts were characterized from the remaining
36 tumours (Table 1 and Figure 3). The most commonly found
alteration was a deletion of eleven bases at the immediate start of
the sequence coded by exon 10 (termed Dex10/11b). This deletion
from the full-length sequence occurred in 65% (62/96) of non-full-
length transcripts and 61% (62/102) of all transcripts. A further six
tumours (one each of Dukes’ stages A, B and C and three Dukes’
stage D tumours) were found to only contain this message variant
(nflt+Dex10/11b) and one tumour (Dukes’ stage D) was found to
contain only nflt and nflt+Dex10/11b transcripts. The Dex10/11b
deletion was frequently found in transcripts with other alterations.
This deletion was also detected in the matched mucosae from
some patients (data not shown), and as such is consistent with the
usage of an alternate internal splice site.
The remaining 29 tumours generated 88 transcripts. DNA
sequence analysis determined that 42% (37/88) of these transcripts
were either nflt or nflt+Dex10/11. The remaining 59% (51/88) of
transcripts contained a variety of alterations including deletions
(44 transcripts), deletion with insertions of novel sequences (six
transcripts) and mutations (one transcript). Sixty-three per cent
(32/51) of these transcripts also contained the Dex10/11 deletion.
A total of 44 transcripts were defined with simple deletions, and
with only two exceptions, deletions occurred in frame and resulted
in the loss of between one and five exons in a single block. The
two exceptions resulted in deletions from the middle of exon 4
(nucleotide 19 of exon 4) to the end of exon 6 and from the middle
of exon 4 (nucleotide 54 of exon 4) to the middle of exon 10
(nucleotide 64 of exon 10; Figure 4). Of the 42 transcripts showing
in-frame deletions 91% (39/43) would result in non-functional
messages as they encompassed, to a greater or lesser degree, the
start site for translation which occurs in exon 5, and included dele-
tion of exons 5–8 (Dex5–8: eight transcripts), deletion of exons
4–6 (Dex4–6: seven transcripts), deletion of exons 4–8 (Dex4–8:
six transcripts), deletion of exons 5–7 (Dex5–7: six transcripts),
deletion of exons 4–7 (Dex4–7: two transcripts) and deletion of
exons 5 and 6 (Dex5–6: two transcripts). The remaining deletion,
which would result in a functional, or potentially functional,
protein was the single deletion of exon 4 (Dex4: four transcripts),
which occurred in one Dukes’ stage B and one Dukes’ stage C
tumour.
Insertion of novel sequences occurred in six transcripts from five
tumours. All of the insertions occurred in combination with in-frame
deletions and included deletion of exons 4–6 with 46 base pairs of
FHIT intron 4 sequences being transcribed in place of the deleted
sequence (this transcript also had an in-frame deletion of exon 8 as
well as the Dex10/11b variation : Dex4–6+ins46+Dex8+Dex10/11b);
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10
ATG TGA
FHIT cDNA
Figure 3 Schematic representation of abberant FHIT transcripts. The classes of transcripts identified are shown in relation to the normal exonic structure of
the FHIT transcript. Dotted lines: novel inserted sequences; x: mutation878 J Elnatan et al
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deletion of exons 6–8 with 101 base pairs of FHIT intron 4 sequences
being transcribed in place of the deleted sequences (this transcript
also transcribed the Dex10/11b variant: Dex6–8+Ins101+Dex10/11b;
Figure 4); deletion of exons 4–7 with replacement of the deleted
sequences with a 138 base sequence of unknown origin with high
homology to Alu repeats (two transcripts, with the Dex10/11b variant
in one: Dex4–7+Ins138 and Dex4–7+Ins138+Dex10/11); deletion of
exons 5–7 with replacement of the deleted sequences with 93 bases
of an unknown sequence (this transcript also transcribed the
Dex10/11bvariant: Dex5–7+Ins93+Dex10/11b) and deletion of exons
4–6 with replacement of the deleted sequences with 14 bases of
sequence of unknown origin (Dex4–6+Ins14).
Interestingly, all of the insertions occurred in Dukes’ stage B
tumours (Table 1) a distribution that is statistically significant
(tumours with inserted transcripts, Dukes’ stage B: 42% [5/13] >
tumours with inserted transcripts, Dukes’ stage A, C, D: 0%
[0/33];  P < 0.001; Fisher’s exact test).
One single-point mutation was detected, a CAA to CTA trans-
version at nucleotide 37 in exon 5 of tumour 2 (nflt+pm37Q-L),
which would result in the replacement of a glutamine with a leucine
(Figure 4). This tumour is Dukes’ stage D, and it is clear that the
mutation is present on only one of the two alleles and the second
allele is present and being transcribed approximately equally.
Silent base changes were noted in 32 transcripts from 18
patients. The changes consisted of GCC to GCT at Ala88 (exon 7,
nucleotide 15); GTC to GTT at Val97 (exon 8, nucleotide 12) and
CAT to CAC at His98 (exon 8, nucleotide 15). Two of these
changes (Ala88 and His98) have been previously identified as
polymorphisms (Mao et al, 1996; Thiangalingam et al, 1996; Fong
et al, 1997) and the third (Val97) was detected in the mucosae of
selected patients again indicative of a polymorphism. The Ala88
polymorphism was detected in only one patient, while the His98
was detected in one-third (15/45) of all patients. Five patients
carried the novel Val97 polymorphism. Three of these patients also
had the His98 polymorphism. In contrast to others who have
examined these polymorphisms in cell lines (Mao et al, 1996),
these polymorphisms were frequently detected in a heterozygous
pattern (data not shown), suggesting that both alleles of FHIT were
present and actively transcribing, although homozygous expres-
sion was also seen (Figure 2).
DISCUSSION
While FHIT and PKCI-1 are both members of the family of histi-
dine triad proteins (HIT proteins), they are clearly differentially
involved in tumorigenesis. Extensive analysis of PKCI-1 tran-
scripts failed to find any alteration at the sequence level in a cohort
of 45 colorectal adenocarcinomas and their matched normal
mucosae. As such, the extensive preservation of sequence of the
PKCI-1 gene may be suggestive of a vital housekeeping role
within the cell.
In contrast, a range of altered transcripts were detected as being
transcribed from the FHIT gene in the tumour samples. Alterations
included deletion of exons (both in frame and out of frame), inser-
tions of novel sequences and loss of transcripts entirely. At no time
did we detect the production of any aberrant transcripts in the
matched mucosae of the patients, supporting the contention that
these transcripts are tumour specific (Ohta et al, 1996). Altered
transcripts were detected approximately equally in all tumour
stages suggesting that aberrations of FHIT gene transcription are a
relatively early event in colorectal tumorigenesis.
Previous studies on the status of FHIT messages in colorectal
adenocarcinomas have been contradictory (Ohta et al, 1996;
Thiagalingam et al, 1996; Chen et al, 1997). In the original study
by Ohta and colleagues (Ohta et al, 1996) aberrant FHIT tran-
scripts were detected in three out of eight colonic tumours and
analysis of matched normal tissues did not detect any alterations in
the coding sequences. In contrast, Thiagalingam and colleagues
detected only the normal full-length product in 27 of 31 colorectal
cell lines and xenografts (Thiagalingam et al, 1996). Two samples
gave no FHIT product and two samples showed evidence of full-
length product together with smaller gene products, although these
smaller products were not further analysed. More recently Chen
and colleagues (Chen et al, 1997) analysed FHIT transcripts in 21
colorectal tumours. While they detected aberrant transcripts in ten
tumours, they also detected aberrant transcripts in seven of the
matched normal tissues.
The most significant difference between these studies lies in the
use of nested PCR. While Ohta and colleagues (Ohta et al, 1996)
use a two-stage amplification, as do Chen and colleagues (Chen et
al, 1997), Thiagalingam and colleagues (Thiagalingam et al, 1996)
use a single-step amplification and suggest that the high rates of
aberrant transcripts seen by Ohta et al (1996) may be a result of
over-representation of smaller products due to the nature of the
nested PCR protocol. However, it should be noted that at no time
have the studies that have utilized a nested approach suggested that
minor products are present at the same level as the full-length
product. Indeed, Chen et al (1997) note that robust levels of the
full-length product are present in 44 of the 46 tumours examined a
result similar to that found in this study. As such, the question that
needs to be addressed is a possible mechanistic action of the
smaller transcripts in disrupting FHIT function.
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Figure 4 Representative DNA electrophoretograms for transcript variants
of FHIT. Depicted are a typical deletion/insertion aberrant transcript
(A, Dex6–8+Ins101b+Dex10/11b), an atypical out of frame deletion transcript
(B, Dex4*–10*) as well as a rare non-sense mutation (C, nflt+pm37Q-L)HIT genes in colorectal cancer 879
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In this study a total of 86% of tumours examined contained
altered or aberrant FHIT transcripts or expression, including three
tumours that showed no FHIT transcripts at all. However, the most
common transcript alteration was the deletion of 11 bases from the
start of exon 10 (DEx10/11b). This is after the translational stop
codon located in exon 9, and so results in no functional change of
protein coding. The sequence at which the deletion occurs: 5¢-
(deleted. … AG)AT … 3¢ is identical to the sequence at the splice
site between intron 9 and exon 10: 5¢-(intron … ag) AT … 3¢ and
as such most probably represents the usage of an alternate splice
site. Indeed this deletion was observed in normal colonic tissues in
this study (data not shown) as well as in normal and tumourous
tissues in other studies (Mao et al, 1996; Sozzi et al, 1996a;
Hendricks et al, 1997). While it is clear from several gene systems
that sequences in the 3¢-untranslated region of a message can play
a significant role in regulating message stability (Chew et al, 1994;
Zehner et al, 1997; Russell et al, 1998) the presence of these
spliced variants in the normal tissues of some patients makes it
unlikely that this particular splice variant plays a role in tumori-
genesis. If the Dex10/11b variant is considered an alternatively
spliced message with no functional effect then normal FHIT tran-
scripts are found in 26% (12/45) of tumours. One further tumour
(tumour 45) contained only deletions of exon 4, again giving rise
to a normal FHIT protein. In this case normal translation products
would occur in 29% (13/45) of tumours.
Wild-type FHIT is able to suppress tumorigenesis in cell trans-
fection studies (Siprashvili et al, 1997). In our analysis, however,
only 8% (4/45) of tumours have lost the ability to produce func-
tional FHIT transcripts. Two of these are Dukes’ stage D, and two
are Dukes’ stage B. Loss of the ability to produce functional tran-
scripts arises from complete loss or silencing of both alleles (three
tumours) and deletion or insertions in all transcripts in a particular
tumour (one tumour). The remaining 90% of tumours therefore
have the ability to produce some functional FHIT protein. This is
coupled with the observation that the majority of aberrant tran-
scripts are apparently non-functional in that the whole of the FHIT
coding sequence, or a substantial portion of it is deleted.
With only one exception all of the aberrant transcripts described
here retain the sequences coded by exon 9, and it is perhaps of
interest to note that aberrant FHIT transcripts from tumour types
including ovarian, endometrial and cervical (Greenspan et al,
1997; Hendricks et al, 1997; Su et al, 1998), digestive tract (Chen
et al, 1997), lung (Sozzi et al, 1996a; Fong et al, 1997), pancreatic
(Simon et al, 1998), merkel cell carcinoma (Sozzi et al, 1996b),
oesophageal (Michael et al, 1997), head and neck (Mao et al,
1996) and breast (Negrini et al, 1996) similarly retain exon 9
sequences in the aberrant transcripts. This may be particularly
pertinent in the light of sequences present in this exon with high
homology to the Kozaks translation initiation sequence (Kozak,
1984) and a small open reading frame, although as yet no peptide
has been documented as arising from this site.
Point mutation of FHIT has been rarely described. Ahmadian
and colleagues (Ahmadian et al, 1997) reported a G to T point
mutation at nucleotide 651, which resulted in the substitution of a
phenylalanine for the wild-type valine. Further analysis showed
that this mutation was not tumour-specific but was in fact in the
germline of the patient and moreover had been passed to one of the
two daughters of the patient (Ahmadian et al, 1997). A single C to
T mis-sense mutation at codon 61 resulting in a threonine to
methionine mutation has been reported in a gastric signet ring cell
adenocarcinoma has been reported by Gemma and colleagues
(Gemma et al, 1997), although the nature of the amino acid substi-
tution (uncharged polar to non-polar) leaves some doubt as to
whether this is an inactivating mutation. The mutation detected
here results in the substitution of a glutamine with a leucine. The
fact that this substitution (uncharged polar to non-polar) is similar
in nature to that detected by Gemma and colleagues (Gemma et al,
1997) may be of particular significance and suggests that examina-
tion of the function of point-mutated FHIT protein may shed
important light on the normal function of FHIT. However, it must
be noted that this mutation is located in neither the FHIT protein
active site nor near surfaces known to be involved in nucleotide
binding (Lima et al, 1997).
Three different polymorphic variants were detected in 18
patients. Two of these (Ala88 and His 98) have been well docu-
mented (Mao et al, 1996; Thiangalingam et al, 1996; Fong et al,
1997). The third variant was found at the Valine adjacent to the
His98 polymorphism in exon 8, and was detected in five patients.
Its detection in this cohort, which comprised solely Chinese
colorectal cancer patients, may be indicative of a polymorphism
of restricted penetrance. One further polymorphism has been
reported by some authors (Fong et al, 1997) at Glu54 in exon 6,
but this polymorphism was not detected in this cohort.
In our study, with the exception of the usage of the putative alter-
nate splice site in exon 10, we detected no aberrant transcripts in the
matched mucosae from the patients in this cohort. In this respect we
are unable to confirm the results of Chen et al (1997), but rather
support the observations of Ohta et al (1996) in that the production
of aberrant transcripts in colorectal tumours is tumour-specific. The
fact that the proportion of tumours with aberrant transcripts is not
linked to tumour progression would also support a contention that
inactivation of FHIT is a relatively early event in tumorigenesis. As
such further investigations into the mechanism and consequence of
FHIT gene action and inactivation are warranted.
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